Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Pre-IPOs
Unlock full access to global stock IPOs
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
A Look At Viking Therapeutics (VKTX) Valuation As VANQUISH 2 Enrollment Milestone Advances VK2735 Program
Viking Therapeutics (VKTX) has completed patient enrollment for its Phase 3 VANQUISH-2 trial of VK2735, a dual GLP-1/GIP agonist for obesity and type 2 diabetes. Despite recent share price volatility, the company is seen as significantly undervalued by Simply Wall St’s narrative fair value of $92.72, compared to its current price of $32.54. This valuation hinges on the future potential of its obesity franchise, though risks include high R&D spending and reliance on VK2735.